Monday, January 16, 2023 12:06:45 PM
How could HyGro possibly have access to more information than the JAMA physicians?
Nothing is hidden or secret if HyGro knows about it. Explore all the supplements attached to the JAMA publication.
Your statements are 100% verifiably false. It is documented and published. PFS and the original trial protocol were covered extensively in the independent peer review. Furthermore, the implications of pseudo-progression are well-documented in the documents submitted to the JAMA peer-review, and pseudo is well-documented in the medical literature in general.
If you want to learn about the original trial protocol all those years ago, consult JAMA and the peer review documents that JAMA has published and made available worldwide. The links are included on the DCVax-L P3 peer review page at the JAMA Oncology website linked below.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://ceoworld.biz/2022/04/05/top-5-medical-journals-in-the-world-everyone-should-know-about/
The statistical analysis plan was approved by the regulators. Ashkan is a careful and precise brain surgeon—listen to his words:
Dr. Ashkan said this in June 2022. Skip to timestamp 14:55 of the ASCO video.
Dr. Ashkan was the chief investigator of the murcidencel trial for patients in Europe. At King’s College in London, Ashkan is the lead clinician for neuro-oncology and the chair of the King’s Neurosciences Clinical Trial Unit. He is a world-renowned cancer trial expert. A few years ago, Professor Ashkan was named the UK Clinician of the Year by The Brain Tumour Charity. Additionally, Ashkan serves as an advisor to the U.K. government.
https://www.kcl.ac.uk/people/keyoumars-ashkan
https://cdn.jamanetwork.com/ama/content_public/journal/oncology/0/coi220066supp1_prod_1668698380.81699.pdf?Expires=1676780989&Signature=I5OpHDA5H3FIhuKxdijPEWnsIIQq5zwNcKvqL6P5Rjy8uumxSPgPb6sc1Uhl2Wd5mP9GTcsZoXzSlU8Pf2pclbrBsWmZiTnkWo0zhvIql90z~mj5MXSYPZ3gQ0~PQBiPDuTlDqz4xMimD33hw45NPJ6B6oRoWYMxsCI-i6Rb3ZSi3g6Iq5~c~Y8QK5CwrPjd3cnN8qcGvERrm0dDqKfRtDYbWj84UsmsdXKw260NwhXHLJjZPEn2EkM3L~ClimScT7ASS9Tcpkoz8Ttw7sf4fe6Iei-Y6hdgg1tY~Tx~zYMftcTOSNQrE3bcxfVcfL7ID0jE5zCGgf1DO9pbbhfrUQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA
Contact JAMA: jamaonc@jamanetwork.org
Nothing is hidden or secret if HyGro knows about it. Explore all the supplements attached to the JAMA publication.
Your statements are 100% verifiably false. It is documented and published. PFS and the original trial protocol were covered extensively in the independent peer review. Furthermore, the implications of pseudo-progression are well-documented in the documents submitted to the JAMA peer-review, and pseudo is well-documented in the medical literature in general.
If you want to learn about the original trial protocol all those years ago, consult JAMA and the peer review documents that JAMA has published and made available worldwide. The links are included on the DCVax-L P3 peer review page at the JAMA Oncology website linked below.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://ceoworld.biz/2022/04/05/top-5-medical-journals-in-the-world-everyone-should-know-about/
The statistical analysis plan was approved by the regulators. Ashkan is a careful and precise brain surgeon—listen to his words:
Dr. Ashkan said this in June 2022. Skip to timestamp 14:55 of the ASCO video.
Dr. Ashkan was the chief investigator of the murcidencel trial for patients in Europe. At King’s College in London, Ashkan is the lead clinician for neuro-oncology and the chair of the King’s Neurosciences Clinical Trial Unit. He is a world-renowned cancer trial expert. A few years ago, Professor Ashkan was named the UK Clinician of the Year by The Brain Tumour Charity. Additionally, Ashkan serves as an advisor to the U.K. government.
https://www.kcl.ac.uk/people/keyoumars-ashkan
https://cdn.jamanetwork.com/ama/content_public/journal/oncology/0/coi220066supp1_prod_1668698380.81699.pdf?Expires=1676780989&Signature=I5OpHDA5H3FIhuKxdijPEWnsIIQq5zwNcKvqL6P5Rjy8uumxSPgPb6sc1Uhl2Wd5mP9GTcsZoXzSlU8Pf2pclbrBsWmZiTnkWo0zhvIql90z~mj5MXSYPZ3gQ0~PQBiPDuTlDqz4xMimD33hw45NPJ6B6oRoWYMxsCI-i6Rb3ZSi3g6Iq5~c~Y8QK5CwrPjd3cnN8qcGvERrm0dDqKfRtDYbWj84UsmsdXKw260NwhXHLJjZPEn2EkM3L~ClimScT7ASS9Tcpkoz8Ttw7sf4fe6Iei-Y6hdgg1tY~Tx~zYMftcTOSNQrE3bcxfVcfL7ID0jE5zCGgf1DO9pbbhfrUQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA
Contact JAMA: jamaonc@jamanetwork.org
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
